PEPTIDE DOSSIER · PRACTICAL TOOLS
Compare evidence for one question
Read study populations, designs, follow-up and endpoints side by side.
These studies differ in participants, run-in treatment, behavioral support and endpoints. Side-by-side presentation is indirect evidence, not a pooled efficacy ranking.
| Study | Compound | Population | Design / follow-up | Endpoint | Limits |
|---|---|---|---|---|---|
| STEP 1 | Semaglutide | Adults with overweight/obesity without diabetes | Randomized, double-blind, placebo-controlled; 68 weeks | Percent change in body weight and achieving at least 5% loss | Lifestyle intervention accompanied both groups; this is not a head-to-head drug comparison. |
| STEP 2 | Semaglutide | Adults with overweight/obesity and type 2 diabetes | Randomized, double-blind, double-dummy, placebo-controlled; 68 weeks | Percent change in body weight and achieving at least 5% loss | Diabetes population; results should not be substituted for STEP 1 or compared as if randomized across trials. |
| STEP 3 | Semaglutide | Adults with overweight/obesity without diabetes | Randomized, double-blind, placebo-controlled, with intensive behavioral therapy; 68 weeks | Percent change in body weight and achieving at least 5% loss | Initial low-calorie diet and intensive behavioral support limit comparisons with less intensive programs. |
| SURMOUNT-1 | Tirzepatide | Adults with overweight/obesity without diabetes | Randomized, double-blind, placebo-controlled; 72 weeks | Percent change in body weight and achieving at least 5% loss | Separate treatment groups and lifestyle support; do not compare raw percentages with another trial as a randomized contrast. |
| SURMOUNT-2 | Tirzepatide | Adults with overweight/obesity and type 2 diabetes | Randomized, double-blind, placebo-controlled; 72 weeks | Percent change in body weight and achieving at least 5% loss | Diabetes population and specified study regimens; not interchangeable with SURMOUNT-1. |
| SURMOUNT-3 | Tirzepatide | Adults without diabetes who lost at least 5% during intensive lifestyle intervention | Randomized, double-blind, placebo-controlled after lifestyle lead-in; 12-week lead-in; 72-week randomized treatment | Weight change after randomization and achieving at least 5% further loss | Selected lifestyle responders; total change from lead-in and change after randomization are different quantities. |
For the direct comparison, read the primary paper and its adverse-event and analysis sections together. No treatment choice is inferred from this matrix.